BioXcel Therapeutics Inc (BTAI)
2.085
-0.22
(-9.54%)
USD |
NASDAQ |
May 10, 16:00
2.13
+0.04
(+2.16%)
After-Hours: 18:59
BioXcel Therapeutics Research and Development Expense (Quarterly): 9.934M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.934M |
| September 30, 2023 | 19.62M |
| June 30, 2023 | 26.97M |
| March 31, 2023 | 27.80M |
| December 31, 2022 | 32.46M |
| September 30, 2022 | 22.06M |
| June 30, 2022 | 17.91M |
| March 31, 2022 | 18.56M |
| December 31, 2021 | 12.52M |
| September 30, 2021 | 11.93M |
| June 30, 2021 | 13.51M |
| March 31, 2021 | 14.74M |
| December 31, 2020 | 11.40M |
| September 30, 2020 | 16.32M |
| Date | Value |
|---|---|
| June 30, 2020 | 17.91M |
| March 31, 2020 | 12.37M |
| December 31, 2019 | 6.495M |
| September 30, 2019 | 7.122M |
| June 30, 2019 | 6.506M |
| March 31, 2019 | 5.674M |
| December 31, 2018 | 6.018M |
| September 30, 2018 | 3.821M |
| June 30, 2018 | 1.781M |
| March 31, 2018 | 2.938M |
| December 31, 2017 | 1.426M |
| September 30, 2017 | 0.619M |
| June 30, 2017 | 0.324M |
| March 31, 2017 | 0.321M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.495M
Minimum
Dec 2019
32.46M
Maximum
Dec 2022
16.11M
Average
14.74M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Synlogic Inc | 10.14M |
| Cormedix Inc | 2.289M |
| Bristol-Myers Squibb Co | 2.695B |
| Verastem Inc | 22.50M |
| Ocular Therapeutix Inc | 16.20M |